Welcome to our dedicated page for Morgan Stanley SEC filings (Ticker: MS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Morgan Stanley’s disclosures are a treasure trove of information on everything from trading Value-at-Risk to the health of its $4T wealth-management franchise. But finding those details inside a 300-page report is tedious. This page curates every filing the firm submits to EDGAR, then layers Stock Titan’s AI so Morgan Stanley SEC filings are explained simply.
Need the latest Morgan Stanley quarterly earnings report 10-Q filing or an Morgan Stanley 8-K material events explained summary? We post them in real time and generate concise AI-powered breakdowns of segment revenue, capital ratios, and liquidity buffers. Curious about management’s trading activity? Our alerts track Morgan Stanley insider trading Form 4 transactions and show Morgan Stanley Form 4 insider transactions real-time, highlighting patterns before they hit the news. When proxy season arrives, the platform pinpoints pay packages inside the Morgan Stanley proxy statement executive compensation section—no more hunting through exhibits.
Professionals use these tools to:
- Compare quarter-over-quarter margins with a click using our Morgan Stanley earnings report filing analysis
- Monitor Morgan Stanley executive stock transactions Form 4 for buy-sell trends
- Read a Morgan Stanley annual report 10-K simplified summary that clarifies risk factors, legal reserves, and capital plans
- Ask natural questions like �understanding Morgan Stanley SEC documents with AI� and receive instant answers
Whether you’re gauging deal pipelines, stress-testing balance sheets, or assessing leadership’s confidence, our AI-powered summaries, expert context, and real-time updates turn raw filings into actionable knowledge—faster than opening a PDF.
Venus Concept Inc. (NASDAQ: VERO) has completed a series of related financing amendments designed to ease near-term liquidity pressure and realign its capital structure.
On 30 June 2025 the Company executed an Exchange Agreement with its senior lender Madryn Health Partners. Two existing secured subordinated convertible notes with aggregate principal of $17.0 million were exchanged for (i) new promissory notes totalling $11.1 million and (ii) 325,651 shares of newly issued Series Y Convertible Preferred Stock priced at $19.96 per share. Each preferred share converts into 9.0909 common shares, implying potential issuance of roughly 3.0 million additional common shares once conversion limits are lifted.
The transaction immediately reduces debt principal by about $5.9 million, shifts a portion of lender exposure into equity and carries no registration requirement under Section 3(a)(9). A Third Amended & Restated Registration Rights Agreement obligates the Company to file a shelf registration for the conversion shares within 60 days after all preferred shares convert.
Concurrently, the Company and Madryn executed several consent and amendment agreements: (1) waiver of minimum liquidity covenants on both the Main Street Priority Loan and the new notes through 31 July 2025, (2) permission to apply the 8 July 2025 interest payment to principal, and (3) a sixteenth amendment to the Bridge Loan extending maturity by one month to 31 July 2025.
To support the larger preferred issuance, Venus filed a Certificate of Amendment increasing authorized Series Y shares from 1.2 million to 1.5 million. A shareholder vote will be sought to remove Nasdaq-related conversion limits.
Overall, the package provides short-term covenant relief and modest debt reduction but adds potential equity dilution and highlights ongoing liquidity constraints, with several key maturities now deferred only to late July 2025.
Venus Concept Inc. (NASDAQ: VERO) has completed a series of related financing amendments designed to ease near-term liquidity pressure and realign its capital structure.
On 30 June 2025 the Company executed an Exchange Agreement with its senior lender Madryn Health Partners. Two existing secured subordinated convertible notes with aggregate principal of $17.0 million were exchanged for (i) new promissory notes totalling $11.1 million and (ii) 325,651 shares of newly issued Series Y Convertible Preferred Stock priced at $19.96 per share. Each preferred share converts into 9.0909 common shares, implying potential issuance of roughly 3.0 million additional common shares once conversion limits are lifted.
The transaction immediately reduces debt principal by about $5.9 million, shifts a portion of lender exposure into equity and carries no registration requirement under Section 3(a)(9). A Third Amended & Restated Registration Rights Agreement obligates the Company to file a shelf registration for the conversion shares within 60 days after all preferred shares convert.
Concurrently, the Company and Madryn executed several consent and amendment agreements: (1) waiver of minimum liquidity covenants on both the Main Street Priority Loan and the new notes through 31 July 2025, (2) permission to apply the 8 July 2025 interest payment to principal, and (3) a sixteenth amendment to the Bridge Loan extending maturity by one month to 31 July 2025.
To support the larger preferred issuance, Venus filed a Certificate of Amendment increasing authorized Series Y shares from 1.2 million to 1.5 million. A shareholder vote will be sought to remove Nasdaq-related conversion limits.
Overall, the package provides short-term covenant relief and modest debt reduction but adds potential equity dilution and highlights ongoing liquidity constraints, with several key maturities now deferred only to late July 2025.
Wayfair Inc. (symbol W) has filed a Form 144 indicating the intention to sell 180,943 Class A shares through Fidelity Brokerage Services on or about 01 July 2025. The shares carry an aggregate market value of $9.51 million and represent roughly 0.17 % of the company’s 103.66 million shares outstanding.
The shares were originally acquired on 01 January 2002 as “Founder Shares� received as compensation. Within the past three months, related parties named in the filing—Steven K. Conine and the Conine Family Foundation—have already sold 153,963 shares for total gross proceeds of approximately $6.71 million.
- Proposed sale class: Class A
- Broker: Fidelity Brokerage Services LLC, Smithfield RI
- Exchange: NYSE
- Planned sale date: 07/01/2025
- Recent insider sales (last 3 months): ~154 k shares
While the dollar amount is sizeable, the percentage of outstanding shares is small, suggesting limited direct dilution. Nonetheless, the continued disposition of shares by founder-linked entities may influence investor sentiment.
Form 4 highlights: On 06/30/2025 Genworth Holdings, Inc., which remains the controlling stockholder of Enact Holdings, Inc. (ticker ACT), sold 691,152 Enact common shares to the issuer under an April 30, 2025 Share Repurchase Agreement. The transaction was coded “S� (sale) and priced at $35.4867 per share, a volume-weighted figure set by the agreement. Following the sale, Genworth still owns 120,243,555 shares, representing approximately 81 % of the outstanding stock, and reports the position as direct ownership.
The filing signals incremental execution of the parent-level liquidity strategy while modestly reducing Enact’s public float through an issuer buyback. No derivative securities were involved, and no change in board or executive relationships was disclosed.
Thermo Fisher Scientific Inc. (TMO) filed a Form 4 on July 1, 2025 disclosing that director Jennifer M. Johnson was credited with 76.54 phantom stock units on June 28, 2025 under the company’s Deferred Compensation Plan for Directors. The units, valued at $408.28 each, convert to common stock on a 1-for-1 basis when the director leaves the board or upon a change of control. After the credit, Johnson holds 474.05 stock-equivalent units, all recorded as direct ownership.
The transaction represents routine deferral of quarterly board retainer fees rather than an open-market purchase or sale. With an estimated market value of roughly $31 thousand, the filing is financially immaterial relative to Thermo Fisher’s multi-billion-dollar market capitalization. No options were exercised, no common shares were sold, and the company’s share count and cash position remain unchanged. The filing nevertheless reinforces incentive alignment by tying a portion of Johnson’s compensation to future shareholder returns.
Salesforce, Inc. (CRM) has filed a Form 144 signaling the intended sale of 144,000 common shares through Merrill Lynch on the NYSE around 01 July 2025. At the reference price used in the filing, the transaction is valued at approximately $39.24 million. The seller—whose name and relationship to Salesforce are not disclosed—originally obtained the shares on 22 March 2019 via the exercise of a stock option and paid for them in cash on 22 March 2023. No additional Salesforce shares have been sold by this filer during the past three months. The proposed sale represents roughly 0.015 % of the company’s 956 million shares outstanding, suggesting minimal impact on overall float or control. The filing contains no indication of a Rule 10b5-1 trading plan, nor any remarks beyond the standard certification language.
Everi Holdings Inc. (EVRI) filed a Post-Effective Amendment No. 1 to twelve previously effective Form S-8 registration statements on 1 July 2025. The filing removes from registration all shares of common stock that remain unsold under a range of equity incentive plans dating back to 2006, including the Amended & Restated 2014 Equity Incentive Plan and several legacy Global Cash Access and Multimedia Games plans.
The deregistration is the administrative follow-up to a transformative transaction completed the same day. Under a series of agreements executed on 26 July 2024, Everi and International Game Technology PLC’s (IGT) Gaming & Digital business were simultaneously acquired by Voyager Parent, LLC, an entity owned by funds managed by affiliates of Apollo Global Management. Key closing steps included: (1) IGT transferring its Gaming & Digital assets to a newly formed subsidiary, Spinco; (2) Apollo’s Voyager entities purchasing all Spinco units and the shares of IGT Canada Solutions ULC; and (3) Voyager Merger Sub, Inc. merging with and into Everi, leaving Everi as a wholly owned subsidiary of Apollo-backed Voyager Parent (the “Merger�).
Because Everi will be delisted and its securities deregistered under Section 12(b) of the Exchange Act, the company has terminated all offerings under its outstanding registration statements. Upon effectiveness of this amendment, no additional Everi shares can be issued under the listed employee stock and option plans.
For public investors, the filing signals the formal end of Everi’s status as an SEC-reporting company. For employees and plan participants, any awards not previously settled in connection with the transaction will no longer be serviceable with newly registered shares. No financial results, purchase consideration, or pro-forma figures were disclosed in this document.
Everi Holdings Inc. (EVRI) filed a Post-Effective Amendment No. 1 to twelve previously effective Form S-8 registration statements on 1 July 2025. The filing removes from registration all shares of common stock that remain unsold under a range of equity incentive plans dating back to 2006, including the Amended & Restated 2014 Equity Incentive Plan and several legacy Global Cash Access and Multimedia Games plans.
The deregistration is the administrative follow-up to a transformative transaction completed the same day. Under a series of agreements executed on 26 July 2024, Everi and International Game Technology PLC’s (IGT) Gaming & Digital business were simultaneously acquired by Voyager Parent, LLC, an entity owned by funds managed by affiliates of Apollo Global Management. Key closing steps included: (1) IGT transferring its Gaming & Digital assets to a newly formed subsidiary, Spinco; (2) Apollo’s Voyager entities purchasing all Spinco units and the shares of IGT Canada Solutions ULC; and (3) Voyager Merger Sub, Inc. merging with and into Everi, leaving Everi as a wholly owned subsidiary of Apollo-backed Voyager Parent (the “Merger�).
Because Everi will be delisted and its securities deregistered under Section 12(b) of the Exchange Act, the company has terminated all offerings under its outstanding registration statements. Upon effectiveness of this amendment, no additional Everi shares can be issued under the listed employee stock and option plans.
For public investors, the filing signals the formal end of Everi’s status as an SEC-reporting company. For employees and plan participants, any awards not previously settled in connection with the transaction will no longer be serviceable with newly registered shares. No financial results, purchase consideration, or pro-forma figures were disclosed in this document.
Bank of Montreal (BMO) is issuing US$6.196 million of Senior Medium-Term Notes, Series K � Autocallable Barrier Notes with Contingent Coupons � linked to Lam Research Corp. (LRCX) common stock.
- Contingent Coupon: 1.1925% monthly (�14.31% p.a.) paid only if LRCX closes � Coupon Barrier (67% of Initial Level, $65.12) on the relevant Observation Date.
- Automatic Redemption: Starting 30-Dec-2025, if LRCX closes > Initial Level on any Observation Date, the note is redeemed at par plus the coupon; no further payments occur.
- Maturity / Principal Risk: 03-Aug-2026. If not called and LRCX closes < Trigger Level (67% of Initial), investors lose 1% of principal for every 1% decline (down to zero). If LRCX stays � Trigger Level, principal is returned.
- Issue Economics: Price to public 100%; estimated initial value $972.97 (�97.3% of face) reflecting embedded fees/hedging. Agent’s commission 2.15%.
- Denomination & Liquidity: $1,000 minimum. Unlisted; secondary market, if any, only through BMOCM. Value sensitive to BMO credit spreads and market volatility.
- Credit & Tax: Unsecured BMO obligation; subject to BMO credit risk and complex U.S. tax treatment (pre-paid contingent income-bearing derivative).
The product targets investors seeking high conditional income and limited downside buffer, willing to forego upside above coupons, accept potential principal loss below a 33% decline, and tolerate issuer credit and liquidity risks.
Palo Alto Networks, Inc. (PANW) � Form 144 filing dated July 1, 2025 discloses a proposed secondary sale of 300,000 common shares by family-related trusts through J.P. Morgan Securities LLC. The shares carry an estimated aggregate market value of $61.392 million based on recent prices and represent approximately 0.05 % of the company’s 666.8 million shares outstanding, implying limited ownership dilution because no new shares are being issued.
The trusts involved (Hawk Family Trust and multiple Cliff Family Trust sub-accounts) have been active sellers. Over the previous three months they completed eight open-market transactions totaling �959,796 shares and $145.6 million in gross proceeds, with sales executed on 11-Apr-2025, 1-May-2025 and 2-Jun-2025. The forthcoming 300 k-share block would lift the rolling four-month total to roughly 1.26 million shares.
All sales are made pursuant to Rule 144, which permits resale of restricted or control securities subject to volume, manner-of-sale and notice requirements. The seller certifies that no undisclosed material adverse information is known and, if applicable, that any Rule 10b5-1 trading plan was adopted on the date indicated.
Investment takeaways:
- The filing signals continued insider-related supply but on a scale unlikely to materially affect PANW’s float or trading liquidity.
- Because these are secondary sales, no cash flows to the company; proceeds accrue solely to the trusts.
- Investors may nevertheless monitor insider sentiment, especially given the nine-month cadence of sizable disposals.